SEATTLE, April 25, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that today Steven C. Quay, M.D., Ph.D., Atossa’s President and CEO, is providing an update on the Company’s clinical programs at the Precision: Breast Cancer World R&D Summit at 2:00 pm ET.
Dr. Quay’s presentation is titled, “A Twenty-First Century Approach: From Primary Prevention to Intraductal Immunotherapy,” and will include the following updates:
Ongoing Phase 2 Study: Dosing has been completed in Atossa’s Phase 2 clinical study of topical Endoxifen to reduce mammographic breast density. Analysis of the results is underway and expected to be announced this quarter.
Expanded Access Program: The first safety end point has been successfully achieved in the FDA-approved expanded access program using Atossa’s proprietary oral Endoxifen to treat a single patient following breast cancer surgery. The patient in this study continues to experience few side effects from Endoxifen.
Intraductal Immunotherapy Program: Atossa recently completed the first phase of a preclinical study using Atossa’s proprietary intraductal delivery technology. Imaging of the mammary ducts of mice showed that dye was successfully dispersed throughout the mammary duct system. Based on these encouraging results, Atossa is advancing to the next preclinical phase which involves the intraductal administration of immune modulating formulations. This preclinical work will form the basis for advancing the intraductal delivery program into humans and to ultimately deliver immunotherapy to treat breast cancer using Atossa’s proprietary intraductal delivery technology.
About Precision: Breast Cancer World R&D Summit
The Precision Breast Cancer World R&D Summit is an exclusive, annual biopharma summit providing insights into the research and development of cutting-edge treatments for Breast Cancer and a networking forum for precision medicine leaders in this space. From therapeutics to diagnostics, the summit brings together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations. The discussion and presentations are based around the latest trends in personalized medicine, using case studies covering early discovery to clinical development.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa's drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
CFO and General Counsel
Office: 866 893-4927
Investor Relations Contact:
377 Oak Street
Garden City, NY 11530
Office: 516 222-2560